Business Context and Reporting Period
This Form 8-K Current Report was filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc., as indicated in the metadata request) on June 12, 2025, covering events occurring on June 8 and June 9, 2025. The Company is a Delaware corporation trading on the Nasdaq Capital Market under the symbol RSLS. The filing primarily details a completed equity offering and the intended use of proceeds related to a proposed merger with Vyome Therapeutics, Inc.
Key Financial Metrics
- Offering Size: 1,054,604 shares of Common Stock.
- Offering Price: $2.50 per share.
- Gross Proceeds: Approximately $2.6 million.
- Placement Agent Fees: Up to 7.0% of gross proceeds plus expense reimbursement.
- Placement Agent Warrants: Warrants to purchase 52,730 shares (5.0% of the offering) at an exercise price of $2.75 per share.
- Net Proceeds: The filing text does not provide a clear value for net proceeds after deducting fees and expenses.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational or balance sheet metrics.
Material Changes
The primary material change is the completion of a registered direct offering on June 9, 2025, resulting in the issuance of approximately 1.05 million new shares. This transaction increases the Company's share count and provides immediate capital. The filing notes that the offering was made pursuant to an effective shelf registration statement (Form S-3) declared effective on May 14, 2025.
Guidance, Outlook, and Management Commentary
- Use of Proceeds: The Company intends to use net proceeds for general corporate purposes, specifically including expenses related to a previously announced proposed merger with Vyome Therapeutics, Inc. and the sale of substantially all assets to Ninjour Health International Limited.
- Regulation FD Disclosure: A press release announcing the pricing of the shares was issued on June 9, 2025.
- Risks and Contingencies: The filing incorporates the Placement Agency Agreement by reference but explicitly states that representations and warranties are for the benefit of the contracting parties only and do not provide factual information regarding the Company's business to investors. Investors are directed to read periodic reports for full risk disclosures.
Important Facts for Investor Verification
- Verify the exact net proceeds received after deducting the 7.0% placement fee and offering expenses.
- Confirm the current status and timeline of the proposed merger with Vyome Therapeutics, Inc. and the asset sale to Ninjour Health International Limited.
- Review the full text of the Placement Agency Agreement (Exhibit 10.1) and Placement Agent Warrant (Exhibit 4.1) for specific covenants and warrant terms.
- Check subsequent filings for the impact of the new share issuance on earnings per share and total outstanding share count.